WILMINGTON, MA--(Marketwired - Jun 4, 2013) - Implant Sciences Corporation (
IDEC is co-hosted by the Federal Drug Control Service of the Russian Federation and the United States Drug Enforcement Agency. This 30 th annual conference is expected to draw representatives from more than 130 countries, 10 of the largest international organizations including Organization for Security and Co-operation in Europe (OSCE), as well as heads of state ministries and agencies.
The international drug enforcement community, in Russia and the CIS countries in particular, has identified 'spice' drugs as a serious threat to society. Spice drugs are common herbs and spices that have been sprayed with cannabinoids, or synthetic compounds that mimic the effects of marijuana or hashish. Spice drugs are difficult to detect, making enforcement a challenge. The QS-B220's ability to detect trace levels of any given chemical uniquely positions it as the key tool to detect spice drugs. This capability will be highlighted at IDEC.
"The drug detection market is an opportunity we intend to pursue with greater focus. This international conference is an important venue for us to highlight our systems' suitability for various drug detection applications," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones .
"We look forward to showcasing the drug and explosives detection technology of Implant Sciences' Quantum Sniffers to the high-profile audience at IDEC. It is our belief that Quantum Sniffers have impressive market prospects because of their strong performance capabilities. We are proud to include these devices as a part of our security offering to our customers in Russia and CIS," said Dr. Andrey Prozorov, Director of Security Systems Department at Borlas Consulting Group.
Borlas Security Systems, a subsidiary of Borlas Consulting Group , specializes in building industry oriented complex security systems based on loss prevention and complete integrated solutions. Founded in 1991, Borlas is a leading consulting group in Russia and CIS states, offering its expertise in the creation of effective management methods and tools to its clients and currently ranks third among the top Hundred Russian Consulting Groups.
About the Quantum Sniffer™ QS-B220 Desktop Explosives and Drugs Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com .
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact: Implant Sciences Corporation Company Contact: Glenn Bolduc CEO 978-752-1700 Email Contact or Investor Contact: Laurel Moody 646-810-0608 Email Contact
